Literature DB >> 8568594

Multiple genetic alterations in malignant metastatic insulinomas.

K Pavelić1, R Hrasćan, S Kapitanović, N Karapandza, Z Vranes, M Belicza, B Kruslin, T Cabrijan.   

Abstract

Proto-oncogenes, growth factors/receptors, and tumour suppressor genes were analysed in malignant metastatic insulinomas. Normal pancreas showed only a moderate immunoreaction for c-myc proto-oncogene and a strong reaction for insulin. Benign insulinomas were slightly or moderately positive for transforming growth factor alpha (TGF alpha), weakly positive for epidermal growth factor receptor (EGF-R), and strongly positive for c-myc and insulin. In malignant insulinomas, besides a strong immunoreaction for c-myc and TGF alpha, activation of c-K-ras and overexpression of p53 protein were found. Insulin reaction was moderate or strong. Three out of six malignant insulinomas displayed a c-K-ras point mutation at codon 12. All mutations were guanine to cytosine transversion, resulting in amino acid substitution, glycine to arginine. Mutations were present in metastatic insulinomas only. Patients with mutated c-K-ras oncogene had overexpression of p53 protein as well as c-myc and TGF alpha overexpression. Our results support the view that malignant progression is a consequence of more than one genetic lesion and suggest that activation of myc, TGF alpha an ras genes plays a role in a multistep process of tumour progression, perhaps serving as an initiating event.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8568594     DOI: 10.1002/path.1711770410

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

2.  A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications.

Authors:  D C Chung; A P Smith; D N Louis; F Graeme-Cook; A L Warshaw; A Arnold
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 3.  Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors.

Authors:  Susanne van Eeden; G Johan A Offerhaus
Journal:  Virchows Arch       Date:  2005-10-12       Impact factor: 4.064

4.  Evidence for the homeostatic regulation of induced beta cell mass expansion.

Authors:  M A Lipsett; E B Austin; M L Castellarin; J Lemay; L Rosenberg
Journal:  Diabetologia       Date:  2006-10-03       Impact factor: 10.122

5.  In vivo proliferation of differentiated pancreatic islet beta cells in transgenic mice expressing mutated cyclin-dependent kinase 4.

Authors:  S Hino; T Yamaoka; Y Yamashita; T Yamada; J Hata; M Itakura
Journal:  Diabetologia       Date:  2004-10-06       Impact factor: 10.122

6.  Origin and Genetic Background of Insulinomas.

Authors:  G. Rindi; M. E. Candusso; A. L. Marchetti
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

7.  Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Tomislav Vladušić; Davor Tomas; Monika Logara; Josip Skoko; Reno Hrašćan
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

8.  Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.

Authors:  Stella Pelengaris; Sylvie Abouna; Linda Cheung; Vasiliki Ifandi; Sevasti Zervou; Michael Khan
Journal:  BMC Biol       Date:  2004-12-21       Impact factor: 7.431

9.  The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.

Authors:  C Wong; S V Laddha; L Tang; E Vosburgh; A J Levine; E Normant; P Sandy; C R Harris; C S Chan; E Y Xu
Journal:  Cell Death Dis       Date:  2014-10-09       Impact factor: 8.469

Review 10.  Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors.

Authors:  Irina A Lubensky; Zhengping Zhuang
Journal:  Endocr Pathol       Date:  2007       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.